|Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression.|
|PMID: 14962949 Owner: NLM Status: MEDLINE|
|OBJECTIVE: Clinical studies have demonstrated that hyperglycaemia represents a major risk factor in the development of the endothelial impairment in diabetes, which is the first step in vascular dysfunction. Using non-obese diabetic mice, we have evaluated the role of the adrenergic system and eNOS on progression of the disease METHODS AND RESULTS: When glycosuria is high (20 to 500 mg/dL), there is a selective reduction in the response to alpha1 and beta2 agonists but not to dopamine or serotonin. When glycosuria is severe (500 to 1000 mg/dL), there is a complete ablation of the contracture response to the alpha1 receptor agonist stimulation and a marked reduced response to beta2 agonist stimulation. This effect is coupled with a reduced expression of alpha1 and beta2 receptors, which is caused by an inhibition at transcriptional level as demonstrated by RT-PCR. In the severe glycosuria (500 to 1000 mg/dL), although eNOS expression is unchanged, caveolin-1 expression is significantly enhanced, indicating that high glucose plasma levels cause an upregulation of the eNOS endogenous inhibitory tone. These latter results correlate with functional data showing that in severe glycosuria, there is a significant reduction in acetylcholine-induced vasodilatation. CONCLUSIONS: Our results show that in diabetes development, there is a progressive selective downregulation of the alpha1 and beta2 receptors. At the same time, there is an increased expression of caveolin-1, the endogenous eNOS inhibitory protein. Thus, caveolin-1 could represent a new possible therapeutic target in vascular impairment associated with diabetes.|
|Mariarosaria Bucci; Fiorentina Roviezzo; Vincenzo Brancaleone; Michelle I Lin; Annarita Di Lorenzo; Carla Cicala; Aldo Pinto; William C Sessa; Silvana Farneti; Stefano Fiorucci; Giuseppe Cirino|
Related Documents :
|15102549 - Neuronal nicotinic acetylcholine receptors as drug targets.
10751429 - Ub-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* ...
9131719 - Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic a...
1517779 - Conformational studies on (+)-anatoxin-a and derivatives.
19027759 - Nicotinic and muscarinic cholinergic receptors coexist on gabaergic nerve endings in th...
16550589 - Nicotinic acetylcholine receptor structure and function in the efferent auditory system.
22337809 - Selective trif-dependent signaling by a synthetic toll-like receptor 4 agonist.
7624049 - Possible involvement of botulinum adp-ribosyltransferase sensitive low molecular g-prot...
21306119 - Corticosteroid hormone receptors and prereceptors as new biomarkers of the illegal use ...
|Type: Comparative Study; Journal Article Date: 2004-02-12|
|Title: Arteriosclerosis, thrombosis, and vascular biology Volume: 24 ISSN: 1524-4636 ISO Abbreviation: Arterioscler. Thromb. Vasc. Biol. Publication Date: 2004 Apr|
|Created Date: 2004-04-02 Completed Date: 2004-08-05 Revised Date: 2009-11-19|
Medline Journal Info:
|Nlm Unique ID: 9505803 Medline TA: Arterioscler Thromb Vasc Biol Country: United States|
|Languages: eng Pagination: 721-6 Citation Subset: IM|
|Department of Experimental Pharmacology, Faculty of Pharmacy, University of Naples, Italy.|
|APA/MLA Format Download EndNote Download BibTex|
Caveolins / biosynthesis, genetics, physiology*
Diabetes Mellitus, Type 1 / physiopathology*
Diabetic Angiopathies / physiopathology*
Dopamine / pharmacology
Down-Regulation / drug effects
Glycosuria / etiology, physiopathology
Hyperglycemia / etiology, physiopathology
Isoproterenol / pharmacology
Mice, Inbred NOD
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide / physiology
Nitric Oxide Synthase / antagonists & inhibitors, genetics, physiology
Nitric Oxide Synthase Type II
Nitric Oxide Synthase Type III
Phenylephrine / pharmacology
Receptor, Insulin / chemistry
Receptors, Adrenergic, alpha-1 / biosynthesis, deficiency*, drug effects, genetics
Receptors, Adrenergic, beta-2 / biosynthesis, deficiency*, drug effects, genetics
Recombinant Fusion Proteins / physiology
Serotonin / pharmacology
Vasodilation / physiology
|0/Adrenergic beta-Agonists; 0/CAV1 protein, human; 0/Cav1 protein, mouse; 0/Caveolin 1; 0/Caveolins; 0/Receptors, Adrenergic, alpha-1; 0/Receptors, Adrenergic, beta-2; 0/Recombinant Fusion Proteins; 10102-43-9/Nitric Oxide; 50-67-9/Serotonin; 50903-99-6/NG-Nitroarginine Methyl Ester; 59-42-7/Phenylephrine; 7683-59-2/Isoproterenol; EC 18.104.22.168/NOS3 protein, human; EC 22.214.171.124/Nitric Oxide Synthase; EC 126.96.36.199/Nitric Oxide Synthase Type II; EC 188.8.131.52/Nitric Oxide Synthase Type III; EC 184.108.40.206/Nos3 protein, mouse; EC 220.127.116.11/Receptor, Insulin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascul...
Next Document: Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and ...